Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR5 and a preparation method and the application thereof. The amino acid sequence of said mutant is SEQ ID NO: 2. The TRAIL CPPs-like mutant selectively transforms the amino acid coding sequence of No. 114-118 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERG to RRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence and glycine into arginine on the 118th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of five arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL CPPs-like mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.
Abstract: A TRAIL cell-penetrating peptide (CPPs)-like mutant MuR6 and a preparation method and the application thereof. The amino acid sequence of the mutant is SEQ ID NO: 2. The mutant selectively transforms the amino acid coding sequence of No. 114-119 of the outer fragment of the TRAIL wild-type protein cell membrane from VRERGP to RRRRRR, i.e., mutates valine into arginine on the 114th coding sequence, glutamic acid into arginine on the 116th coding sequence, glycine into arginine on the 118th coding sequence and proline into arginine on the 119th coding sequence, turning the coding sequence of N-terminal of the mutant protein into that of six arginines and making it a protein containing CPPs-like structure. Having a superior therapeutic effect on different types of tumor, the TRAIL mutant is a new generation of high-efficient drug for inducing tumor apoptosis of much potential.
Abstract: The invention mainly relates to the field of genetic engineering drugs, in particular to a mutant cDNA sequence obtained by mutating valine at position 114, glutamate at position 116, glycine at position 118, proline at position 119 and glutamine at position 120 in an amino acid sequence at positions 114-281 of an extracellular fragment of a wild-type TRAIL protein respectively into arginines, so as to allow amino acids at positions 114-121 of the TRAIL protein to form a 8-consecutive arginine sequence, and then by gene synthesis and PCR mutation and splicing; and the TRAIL mutant has excellent therapeutic effect for a variety of tumors of different types, and is a new generation of promising drug for highly efficiently inducing tumor cell apoptosis.
Abstract: The invention mainly relates to the field of genetic engineering drugs, in particular to a mutant cDNA sequence obtained by mutating valine at position 114, glutamate at position 116, glycine at position 118, proline at position 119 and glutamine at position 120 in an amino acid sequence at positions 114-281 of an extracellular fragment of a wild-type TRAIL protein respectively into arginines, so as to allow amino acids at positions 114-121 of the TRAIL protein to form a 8-consecutive arginine sequence, and then by gene synthesis and PCR mutation and splicing; and the TRAIL mutant has excellent therapeutic effect for a variety of tumors of different types, and is a new generation of promising drug for highly efficiently inducing tumor cell apoptosis.